- Fallon JT. Pathology of myocardial infarction and reperfusion. In: Fuster V, Ross R and Topol EJ, eds: Atherosclerosis and Coronaiy Artery Disease. Philadelphia: Eippincott-Raven, 1996, 791-796.
- Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 310-318.
- Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989; 14:813-836.
- Coller BS. Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med 1992; 43: 171-180.
- Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114.
- Pumphrey CW, Dawes J. Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischmie heart disease and after acute myocardial infarction. Am J Cardiol 1982; 50: 1258-1261.
- Hughes A, Daunt S, Vass G, Wickes J. In vivo platelet activation following myocardial infarction and acute coronary ischemia. Thromb Haemost 1982; 48: 133-135.
- Fitzgerald DJ, Catella F, Roy E, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-150.
- Fuchs J, Weinberger I, Rotenberg Z, Joshua H, Almozlino A, Agmon J. Circulating aggregated platelets in coronary artery disease. Am J Cardiol 1987; 60: 534-537.
- ISIS-2 (Second International Study of lnfarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
- Roux S, Christeller S, Eudin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis. A meta-analysis. J Am Coll Cardiol 1992; 19: 671-677.
- Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
- Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. Chest 1995; 108: 471s-485s.
- The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
- Grines CE, Browne KF, Marco J, et al, for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-679.
- Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous fibrinolysis therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093-2098.
- Brodie BR, Grines CE, Ivanhoe R, et al. Six-month clinical and angiographie follow-up after direct angioplasty for acute myocardial infarction: final results from the primaiy angioplasty registry. Circulation 1994; 90: 156-162.
- Weinberger I, Fuchs J, Davidson E, Rotenberg Z. Circulating aggregated platelets, number of platelets per aggregate, and platelet size during acute myocardial infarction. Am J Cardiol 1992; 70: 981-983.
- Gasperetti CM, Conias SL, Cimple LW, Powers LR. Platelet activation during coronary angioplasty in humans. Circulation 1993; 88: 2728-2734.
- Bates LR, McGillem MJ, Mickelson JK, Pitt B, Mancini GB. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991; 84: 2463-2469.
- Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-2380.
- Tcheng JL, Lllis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Lab 7L3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-1764.
- Mascelli MA, Lance LT, Damaraju L, Wagner CL, Weisman HL, Jordan RL. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-1688.
- Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-1227.
- Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/llla blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27: 536-542.
- Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/llla receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77: 1045-1051.
- EPlC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/llla receptor in high-risk coronaiy angioplasty. N Engl J Med 1994; 330: 956-961.
- The IMPACT II Investigators. Randomized placebocontrolled trial of effect of eptifibatide on complications of percutaneous coronaiy intervention: IMPACT-II Lancet 1997; 349: 1422-1428.
- The RLSTORE Investigators. Effects of platelet glycoprotein IIb/llla blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronaiy angioplasty. Circulation 1997; 96: 1445-1453.
- Grantham JA, Hasdai D, Kopecky SL, Holmes DR. Platelet glycoprotein IIb/llla receptor inhibition during PTCA for acute MI. J Am Coll Cardiol 1998; 31: 231A (abstr).
- Brener SJ, Barr LA, Burchenal JLB, et al, for the RAPPORT Investigators. A randomized, placebo-controlled trial of platelet glycoprotein IIb/llla blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-741.
- Neumann LJ, Blasini R, Schmitt C, et al. Lffect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after placement of coronaryartery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
- Coller BS. GP IIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 fab. Thromb Haemost 1997; 78: 730-735.
- Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor ( avß3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96: 1809-1818.
- Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin MAC-1 and blocks adhesion to fibrinogen and 1CAM-1. Arterioscler Thromb Vase Biol. 1997; 17: 528-535.
- Fan ST, Edginton TS. Integrin regulation of leukocyte inflammatory functions: CD11b/CD18 enhancement of tumor necrosis factor-alpha responses of monocytes. J lmmunol 1993; 150; 2972-2980.
- Murphy JF, Bordet JC, Wyler B, et al. The vitronectin receptor (avß3,) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J 1994; 304: 537-542.
- Van den Merkhof LF, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1999; 33: 1528-1532.
- Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154.
- Zijlstra F, De Boer MJ, Hoorntje JCA, et al. A comparison of immediate angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-684.
- GUSTO-IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-1628.
- Montalescot G, Baragan P, Wittenberg O, et al. Clinical benefits of platelet Ub-IIIa blockade with primary coronary stenting in acute myocardial infarction. Results of the randomized double-blind ADMIRAL trial. N Engl J Med 2001; 344: 1895-1903.
- Stone GW. The CADILLAC trial. Presented at the 72nd Scientific Sessions of the American Heart Association, November 10, 1999, Atlanta, GA.
- SPEED Group. Trial of abciximab with and without lowdose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788-2794.
- Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1489-1496.
- Khot UN, Newmann F-J, Brener SJ, et al. Is IIb/IIIa blockade state-of-the-art for catheter-based reperfusion? A metaanalysis of 5 randomized trials in acute myocardial infarction. J Am Coll Cardiol 2001; 37: 368A (abstr).
- Rawitscher D, Levin TN, Cohen I, Feldman T. Rapid reversal of no-Reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diag 1997; 42: 187-190.
- Mark DB, Talley JD, Topol EJ, et al, for the EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemie complications of highrisk coronary angioplasty. Circulation 1996; 94: 629-635.
International Journal of Cardiovascular Interventions
Volume 4, 2001 - Issue 1